Lite Strategy Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 5

Employees

  • Stock Symbol
  • LITS

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $0.80
  • (As of Friday Closing)

Lite Strategy General Information

Description

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.

Contact Information

Formerly Known As
Marshall Edwards, MEI Pharma
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 9920 Pacific Heights Boulevard
  • Suite 150
  • San Diego, CA 92121
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 9920 Pacific Heights Boulevard
  • Suite 150
  • San Diego, CA 92121
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lite Strategy Stock Performance

As of 20-Nov-2026, Lite Strategy’s stock price is $0.80. Its current market cap is $24M with 29.9M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.80 $0.84 $0.69 - $1.99 $24M 29.9M 522K -$1.38

Lite Strategy Financials Summary

As of 30-Sep-2026, Lite Strategy has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 30-Jun-2026 FY 2025 30-Jun-2025 FY 2024 30-Jun-2024
EV 34,432 21,757 (4,015) (25,496)
Revenue 0 0 0 65,297
EBITDA (51,691) (71,417) (16,603) 14,884
Net Income (51,488) (71,150) (15,945) 17,778
Total Assets 58,401 42,692 18,285 41,375
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Lite Strategy Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Lite Strategy‘s full profile, request access.

Request a free trial

Lite Strategy Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug
Drug Discovery
San Diego, CA
5 As of 2026

Wilmington, DE
 

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Lite Strategy Competitors (81)

One of Lite Strategy’s 81 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ayala Pharmaceuticals Corporation Wilmington, DE
Olema Oncology Formerly VC-backed San Francisco, CA
TME Pharma Formerly VC-backed Berlin, Germany
Elicio Therapeutics Formerly VC-backed Boston, MA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
You’re viewing 5 of 81 competitors. Get the full list »

Lite Strategy Patents

Lite Strategy Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024173833-A1 Combination of a cdk inhibitor and a flt3 inhibitor for the treatment of cancer Inactive 16-Feb-2023
WO-2024137472-A2 Combination therapies Inactive 19-Dec-2022
WO-2024137472-A3 Combination therapies Inactive 19-Dec-2022
AU-2023228576-A1 Combination therapy of pi3k inhibitor and pd-1 inhibitor Pending 01-Mar-2022
EP-4486351-A1 Combination therapy of pi3k inhibitor and pd-1 inhibitor Pending 01-Mar-2022 A61K31/5377
To view Lite Strategy’s complete patent history, request access »

Lite Strategy Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lite Strategy Investments & Acquisitions (4)

Lite Strategy’s most recent deal was a Corporate with LitVM for . The deal was made on 18-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
LitVM 18-Jun-2026 Corporate Software Development Applications
Presage Biosciences (anti-cancer drug candidate voruciclib) 05-Sep-2017 Corporate Asset Purchase Buildings and Property
Pathway Therapeutics (Anticancer Drug) 14-Aug-2013 Merger/Acquisition Biotechnology
S*Bio (Cancer Drug Rights) 10-Aug-2012 Corporate Asset Purchase Buildings and Property
To view Lite Strategy’s complete investments and acquisitions history, request access »

Lite Strategy ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

34.7 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Lite Strategy’s complete esg history, request access »

Lite Strategy Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
MEI Pharma (Rights, Title, Interest and Certain Assets Related to ME-344) San Diego, CA

Lite Strategy FAQs

  • When was Lite Strategy founded?

    Lite Strategy was founded in 2000.

  • Where is Lite Strategy headquartered?

    Lite Strategy is headquartered in San Diego, CA.

  • What is the size of Lite Strategy?

    Lite Strategy has 5 total employees.

  • What industry is Lite Strategy in?

    Lite Strategy’s primary industry is Drug Discovery.

  • Is Lite Strategy a private or public company?

    Lite Strategy is a Public company.

  • What is Lite Strategy’s stock symbol?

    The ticker symbol for Lite Strategy is LITS.

  • What is the current stock price of Lite Strategy?

    As of 20-Nov-2026 the stock price of Lite Strategy is $0.80.

  • What is the current market cap of Lite Strategy?

    The current market capitalization of Lite Strategy is $24M.

  • Who are Lite Strategy’s competitors?

    Ayala Pharmaceuticals, Olema Oncology, TME Pharma, Elicio Therapeutics, and Adaptimmune Therapeutics are some of the 81 competitors of Lite Strategy.

  • What is Lite Strategy’s annual earnings per share (EPS)?

    Lite Strategy’s EPS for 12 months was -$1.38.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process